Noninvasive prenatal testing beyond genomic analysis: what the future holds

Area of Science:

• Reproductive Biology
• Genetics
• Molecular Diagnostics

Background:

• Cell-free fetal DNA (cfDNA) in maternal blood revolutionized prenatal testing for chromosomal aneuploidies.
• Noninvasive prenatal testing (NIPT) has become a cornerstone of modern prenatal care.
• Emerging technologies focus on analyzing other cell-free analytes beyond cfDNA.

Purpose of the Study:

• To review advancements in analyzing cell-free fetal RNA and DNA methylation patterns in maternal blood.
• To explore the potential of these analyses for noninvasive monitoring of placental function.
• To highlight their role in screening and identifying pregnancy-associated diseases.

Main Methods:

• Review of current techniques for measuring cell-free fetal RNA (transcriptomics) in maternal plasma.
• Examination of methods for analyzing fetal-specific DNA methylation patterns (methylomics) in maternal blood.
• Assessment of studies demonstrating the feasibility of these molecular analyses for prenatal disease detection.

Main Results:

• Genome-wide fetal transcriptome and methylome data can be obtained from maternal plasma.
• Novel biomarkers for maternal and fetal diseases can be identified through these analyses.
• Studies confirm the feasibility of using RNA and DNA methylation for prenatal disease assessment.

Conclusions:

• Cell-free fetal transcriptomic and methylomic analyses hold significant potential for future prenatal diagnostics.
• These methods offer a pathway for noninvasive monitoring of placental function.
• The findings support a holistic approach to prenatal management through advanced molecular analysis.